190 related articles for article (PubMed ID: 28208617)
1. Inhibition of Autophagy by Deguelin Sensitizes Pancreatic Cancer Cells to Doxorubicin.
Xu XD; Zhao Y; Zhang M; He RZ; Shi XH; Guo XJ; Shi CJ; Peng F; Wang M; Shen M; Wang X; Li X; Qin RY
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208617
[TBL] [Abstract][Full Text] [Related]
2. Deguelin induces PUMA-mediated apoptosis and promotes sensitivity of lung cancer cells (LCCs) to doxorubicin (Dox).
Wang A; Wang W; Chen Y; Ma F; Wei X; Bi Y
Mol Cell Biochem; 2018 May; 442(1-2):177-186. PubMed ID: 29030732
[TBL] [Abstract][Full Text] [Related]
3. Anti-cancer effects of deguelin on human leukemia K562 and K562/ADM cells In Vitro.
Wu Q; Chen Y; Liu H; He J
J Huazhong Univ Sci Technolog Med Sci; 2007 Apr; 27(2):149-52. PubMed ID: 17497282
[TBL] [Abstract][Full Text] [Related]
4. Danthron suppresses autophagy and sensitizes pancreatic cancer cells to doxorubicin.
Chen H; Zhao C; He R; Zhou M; Liu Y; Guo X; Wang M; Zhu F; Qin R; Li X
Toxicol In Vitro; 2019 Feb; 54():345-353. PubMed ID: 30389604
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects of deguelin on H460 human lung cancer cells in vitro and in vivo: Roles of apoptotic cell death and H460 tumor xenografts model.
Hsu YC; Chiang JH; Yu CS; Hsia TC; Wu RS; Lien JC; Lai KC; Yu FS; Chung JG
Environ Toxicol; 2017 Jan; 32(1):84-98. PubMed ID: 26592500
[TBL] [Abstract][Full Text] [Related]
6. Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway.
Murillo G; Peng X; Torres KE; Mehta RG
Cancer Prev Res (Phila); 2009 Nov; 2(11):942-50. PubMed ID: 19861542
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis induction by the natural product cancer chemopreventive agent deguelin is mediated through the inhibition of mitochondrial bioenergetics.
Hail N; Lotan R
Apoptosis; 2004 Jul; 9(4):437-47. PubMed ID: 15192326
[TBL] [Abstract][Full Text] [Related]
8. Deguelin inhibits HCV replication through suppressing cellular autophagy via down regulation of Beclin1 expression in human hepatoma cells.
Liao W; Liu X; Yang Q; Liu H; Liang B; Jiang J; Huang J; Ning C; Zang N; Zhou B; Liao Y; Chen J; Tian L; Ho W; Abdullah AS; Kong L; Liang H; Chen H; Ye L
Antiviral Res; 2020 Feb; 174():104704. PubMed ID: 31917237
[TBL] [Abstract][Full Text] [Related]
9. Deguelin inhibits human hepatocellular carcinoma by antiangiogenesis and apoptosis.
Lee JH; Lee DH; Lee HS; Choi JS; Kim KW; Hong SS
Oncol Rep; 2008 Jul; 20(1):129-34. PubMed ID: 18575727
[TBL] [Abstract][Full Text] [Related]
10. [Effect of deguelin on proliferation and apoptosis of lymphoma Daudi cells and its mechanism].
Liu HL; Chen Y; Cui GH; Wu QL; Chen WH; He J
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):176-80. PubMed ID: 17649631
[TBL] [Abstract][Full Text] [Related]
11. Deguelin promotes apoptosis and inhibits angiogenesis of gastric cancer.
Lee H; Lee JH; Jung KH; Hong SS
Oncol Rep; 2010 Oct; 24(4):957-63. PubMed ID: 20811676
[TBL] [Abstract][Full Text] [Related]
12. Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin.
Jin Q; Feng L; Behrens C; Bekele BN; Wistuba II; Hong WK; Lee HY
Cancer Res; 2007 Dec; 67(24):11630-9. PubMed ID: 18089792
[TBL] [Abstract][Full Text] [Related]
13. Deguelin suppresses cell proliferation via the inhibition of survivin expression and STAT3 phosphorylation in HTLV-1-transformed T cells.
Ito S; Oyake T; Murai K; Ishida Y
Leuk Res; 2010 Mar; 34(3):352-7. PubMed ID: 19781773
[TBL] [Abstract][Full Text] [Related]
14. Psammaplin A induces Sirtuin 1-dependent autophagic cell death in doxorubicin-resistant MCF-7/adr human breast cancer cells and xenografts.
Kim TH; Kim HS; Kang YJ; Yoon S; Lee J; Choi WS; Jung JH; Kim HS
Biochim Biophys Acta; 2015 Feb; 1850(2):401-10. PubMed ID: 25445714
[TBL] [Abstract][Full Text] [Related]
15. Deguelin inhibits vasculogenic function of endothelial progenitor cells in tumor progression and metastasis via suppression of focal adhesion.
Nguyen MP; Lee D; Lee SH; Lee HE; Lee HY; Lee YM
Oncotarget; 2015 Jun; 6(18):16588-600. PubMed ID: 26078334
[TBL] [Abstract][Full Text] [Related]
16. Regulating expressions of cyclin D1, pRb, and anti-cancer effects of deguelin on human Burkitt's lymphoma Daudi cells in vitro.
Liu HL; Chen Y; Cui GH; Wu QL; He J
Acta Pharmacol Sin; 2005 Jul; 26(7):873-80. PubMed ID: 15960896
[TBL] [Abstract][Full Text] [Related]
17. Deguelin, a selective silencer of the NPM1 mutant, potentiates apoptosis and induces differentiation in AML cells carrying the NPM1 mutation.
Yi S; Wen L; He J; Wang Y; Zhao F; Zhao J; Zhao Z; Cui G; Chen Y
Ann Hematol; 2015 Feb; 94(2):201-10. PubMed ID: 25242579
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha.
Oh SH; Woo JK; Jin Q; Kang HJ; Jeong JW; Kim KW; Hong WK; Lee HY
Int J Cancer; 2008 Jan; 122(1):5-14. PubMed ID: 17764071
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Cancer Stem-Like Phenotype by Curcumin and Deguelin in CAL-62 Anaplastic Thyroid Cancer Cells.
Kocdor MA; Cengiz H; Ates H; Kocdor H
Anticancer Agents Med Chem; 2019; 19(15):1887-1898. PubMed ID: 31584382
[TBL] [Abstract][Full Text] [Related]
20. Enhancement radiosensitization of breast cancer cells by deguelin.
Yi T; Li H; Wang X; Wu Z
Cancer Biother Radiopharm; 2008 Jun; 23(3):355-62. PubMed ID: 18593368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
